This review focuses on recent developments in the biology and clinical therapeutics of renal cell carcinoma. Given historically limited advances in this disease, a more thorough understanding and testing of rationally targeted agents is needed.
Introduction
Accumulating knowledge of the underlying biology of renal cell carcinoma (RCC) has led to a greater understanding of this disease. Importantly, this biology is being translated into treatment strategies with the potential to impact clinical outcome. Recent observational studies of small renal masses have better defined the natural history and potential for expectant management. Immunotherapy remains an active area of investigation based on modest clinical benefit and generation of relevant immune responses in vaccination trials. Further, novel therapeutics directed against vascular endothelial growth factor (VEGF) have demonstrated substantial anti-tumor effects in initial trials. This review will examine recent publications relevant to RCC biology and clinical management.
Molecular biology of renal cell carcinoma
Substantial gains have been made in clarifying the genetics of renal cell carcinoma in recent years, particularly in tumors with clear cell histology. A majority of patients with RCC have an inactivated von Hippel-Lindau (VHL) tumor suppressor gene [1] [2] [3] [4] [5] [6] . The effect of this event is deregulated expression of one or both of a family of hypoxia inducible factors (HIF1a and HIF2a) [7] . Mutations that disrupt the tuberous sclerosis complex and other evolving pathways associated with familial hamartoma syndromes also result in dysregulation of HIF2a and VEGF expression that is mediated through unregulated activation of mTOR [8,9 • ,10] . It was recently reported, however, that the HIF factors induce transcription of an overlapping, but not identical set of genes involved in the cellular response to oxygen (O 2 ) deprivation. Specifically, in an expression array analysis of cells expressing exclusively HIF2a, as compared with cells expressing both HIF1a and HIF2a, it was observed that HIF2a has no effect on the expression of glycolytic enzymes [11] . This represents a potentially important distinction in the metabolic activity signature of such tumors. Novel targets of HIF activation were also identified in this screen including a protein called ADRP, a lipid transporter normally expressed in adipose tissue. Interestingly, the expanding list of targets now accounts for much of the unique attributes of conventional renal cell carcinoma: ADRP, neutral lipid accumulation and clear cell histology; VEGF and other angiogenic factors, vascularity; erythropoietin, paraneoplastic polycythemia; IL-6, paraneoplastic fever ( Fig. 1 ).
As the distinct profiles of HIF1a and HIF2a emerge, the expression patterns of these factors have also been appreciated. Individual tumors may express only HIF2a or both factors. The absolute role of either factor is not yet clear.
It has been recently demonstrated that suppression of HIF2a in a renal carcinoma cell line with RNAi was sufficient to inhibit tumor formation in a xenograft assay [12, 13] thus establishing HIF2a as a factor with oncogenic potential. Although most of the early attention in this pathway was focused on the first of these family members to be identified, the implications of HIF1aÿ versus HIF2a-dominant expression in a given tumor remains uncertain.
As our understanding of the genetics behind RCC expands, so does our ability to use molecular markers as indicators of disease prognosis. Much attention has focused on a subset of genes induced in response to HIF activation. One of these genes is carbonic anhydrase IX (CA IX) [14] . This gene may play a role in regulating the intracellular pH during periods of hypoxic stress. Tissue microarray profiling has implicated this target of HIF expression as an important molecular prognostic factor in conventional renal cell carcinoma [15, 16] . Immunostaining for the CAIX (also called G250) protein may provide a potentially straightforward molecular prognostication nomogram, which could be implemented into current clinical prognostic schemas. In addition, evaluation of renal cell carcinoma signatures by gene expression and other array-based profiling continues to be a robust method for histologic classification of the tumors. A recent genome microarray analysis distinguished between the three most common subtypes of RCC (clear cell, papillary, and chromophobe) in 99% of cases [17] . Prospective validation of genes identified by such genomic analyses may enhance histopathological classification, build upon existing predictive and prognostic clinical schemas and, perhaps most importantly, identify therapeutic targets.
Management of small renal masses
The incidence of asymptomatic renal masses has increased in recent years, in large part due to the widespread use of abdominal imaging. Accepted management of small renal masses (generally defined as masses <4 cm in diameter) has been radical or partial nephrectomy with diagnostic and therapeutic intent. Up to 30% of such masses, however, may not represent malignancy upon pathologic examination [18] . Further, patients with significant medical comorbidities may not be surgical candidates. Thus, complementary strategies for management of small renal masses may permit application of nephrectomy to a more appropriately enriched population. Such a strategy may limit surgery for both non-cancerous renal masses and small RCC tumors unlikely to affect patient survival and also for the medically unfit. Prior small, retrospective series have described the limited growth of small renal masses and the low risk of metastatic spread [19, 20] . Three recent series have reported the natural history of small renal masses (Table 1) 22, 23] . In general, masses were incidental, asymptomatic renal lesions that were not initially surgically addressed because of advanced patient age/comorbidities or patient preference. Variable follow-up imaging was performed and tumor growth rate calculated by tumor diameter and/or volume. Surgery was ultimately performed on some patients, either because of tumor growth or patient request. The growth rate was variable with many patients demonstrating no growth or even tumor regression. Limited patient numbers preclude making a definitive correlation between growth rate and tumor grade. No patient in any series developed metastases or died of RCC. Although additional prospective data on larger number of patients is needed, these results support expectant management as an acceptable initial strategy in selected patients with small renal masses including those unfit or unwilling to undergo surgery. Additional tumor characteristics such as gene or protein expression and radiographic appearance should be investigated to provide complementary data to growth rate in the management strategy of these masses.
Pending further investigation of expectant management as well as the emerging technologies of cryotherapy and radiofrequency ablation, surgical removal of small renal masses remains the standard of care. Non-surgical treatment of such patients should be reserved for patients on a clinical trial until more definitive data are available.
Cytokine immunotherapy
Immunotherapy has been the mainstay of treatment for renal cell carcinoma for more than 20 years and continues to evolve. The use of the cytokine agents interferon alpha and interleukin-2 (IL-2), in addition to traditional use as monotherapy for renal cell carcinoma, continue to play a role in investigational combination regimens. Thalidomide has been of particular interest for some time due to potential angiogenic effects. In a recent first-line phase II trial of thalidomide and interferon-alpha an overall response rate of 7% was reported, with an additional one third of patients requiring discontinuation of thalidomide owing to excessive toxicity [24] . Additionally, interim analysis of a randomized phase III study of interferonalpha plus thalidomide versus interferon-alpha alone presented at ASCO 2004 demonstrated similarly discouraging results, with the combination therapy arm failing to demonstrate an advantage over interferon-alpha monotherapy in response rate, quality of life, or overall survival [25 • ]. Cytokines, however, will continue to provide the foundation for investigational combinations, especially with novel molecularly targeted therapies, as discussed elsewhere in this review. Phase I evaluation of interferon-alpha in combination with IL-12, a cytokine gaining interest in this disease, was found to be tolerable, with primary dose limiting toxicity limited to grades 3 and 4 hepatotoxicity and neutropenia/leukopenia [26] . Unique methods of delivering cytokine therapy are also undergoing investigation, in particular, studies of percutaneous CT-guided intratumoral immunotherapy show this mechanism to be technically feasible with relative safety, but the efficacy of this approach remains unknown. Advances in molecular biology described above may also aid in the optimal delivery of cytokines. Expression of carbonic anhydrase IX (G250), a VHL-mediated protein, was recently demonstrated to predict response to high-dose IL-2 [15,27 • ]. Further prospective validation of this observation may allow enrichment of the RCC population for IL-2 response. Investigation of this or other predictive markers with low-dose cytokine therapy or other targeted therapy is of interest.
Cellular immunotherapy
Non-cytokine based immunotherapy continues to be an area of active investigation. Nonmyeloablative transplantation is one mechanism of inducing an immune response in the form of graft versus host disease. A recent report by Igarashi et al. [28] identified in vitro cytotoxic activity of allogeneic NK cells in renal carcinoma cells as a potential mechanism of anti-tumor activity in this modality. A comprehensive review of the pilot trials of allogeneic transplantation demonstrates an important proof of principle that an anti-tumor immune response can be demonstrated in the donor compartment [29] . Many questions regarding this therapy remain, including the optimal protocol of chemotherapy conditioning, the utility of post-transplant donor lymphocyte infusion, and the choice of patients for transplant. Foremost, the absolute benefit of this modality of therapy remains uncertain in the population of patients with advanced renal cell carcinoma, and therefore remains limited to clinical investigations. An additional modality of immunologic treatment undergoing investigation is the expanding strategies of dendritic cell tumor vaccination in all stages of disease. Currently, these strategies are highly specialized and vary tremendously based on the site preparing the vaccine, but have largely coalesced to methods using dendritic cell (DC) carriers of a varied host of tumor antigens. DCs are potent antigen presenting cells and can be incorporated into vaccines by introducing peptides, proteins, RNA, or genes as a source of specific antigens. In addition, whole tumor cells can provide the antigen from tumor cell lysates or the tumor cells can be used to form cellular fusions with the DCs for broad spectrum anti-tumor immune response [30] . A European phase III randomized trial of adjuvant vaccination with an autologous renal tumor cell vaccine in patients with resected T2-3b pN0-3 M0 tumors showed a benefit in 5-year progression-free survival (77.4% in the treated group and 67.8% in the control group) [31] . No overall survival advantage has yet been demonstrated. The vaccine was well tolerated with minimal adverse events. Additional validation of this approach is needed, however, before adopting this modality as standard adjuvant treatment.
In the metastatic setting, one vaccine in development incorporated an allogeneic tumor lysate-pulsed DC product [32] . This investigation also showed no significant toxicity to the vaccine or the adjuvant drug, hemocyanin, used in this investigation. Additionally, an immune response was identified by ELISPOT analysis of IFNg expression and expression of T helper type 1 cytokines. In another vaccine strategy in the metastatic setting, irradiated whole tumor was admixed with GM-CSF as the vaccine platform. This pilot study demonstrated the expected safety immune profile as well as increases in T cell pools consistent with the expected immune response [33] . Vaccination in the setting of renal cell carcinoma demonstrates the generation of potentially relevant immune responses, and remains an active area of study with many remaining issues including the feasibility of centralizing vaccine production and the optimal clinical setting for this treatment modality.
Novel therapeutics
Novel, targeted therapy in metastatic RCC has witnessed an explosion of therapeutic approaches in the past year. Most of these are directed against VEGF based on the inherent VHL gene inactivation underlying RCC as described above. The resulting VHL gene silencing leads to induction of hypoxia-regulated genes including VEGF, a potent pro-angiogenic protein, and platelet-derived growth factor (PDGF), expressed on pericytes, which provide structural support to endothelial cells [34] [35] [36] [37] [38] [39] [40] [41] . Approaches to neutralize the effects of VEGF and PDGF in RCC have thus been explored.
Anti-VEGF antibody
The initial trial of anti-VEGF therapy in metastatic RCC employed bevacizumab, a neutralizing anti-VEGF antibody, in treatment-refractory RCC [42] . One hundred sixteen patients with treatment-refractory, metastatic clear cell RCC were randomized to receive placebo, low-dose (3 mg/kg) bevacizumab or high-dose (10 mg/kg) bevacizumab given intravenously every 2 weeks. Despite a low (10%) objective response rate, a significant prolongation of time to disease progression (TTP) was observed in the high-dose bevacizumab arm. Further, due to stringent progression criteria employed, several patients came off study for disease progression, but with a lower total tumor burden than baseline. This fact may have allowed underestimation of the ultimate treatment effect of this approach. This trial first identified the anti-tumor potential of anti-VEGF approaches in RCC. Patients with disease progression on placebo in the above study were eligible to enter a separate study and receive low-dose bevacizumab alone or low-dose bevacizumab plus thalidomide escalated intra-patient from 200 mg to 800 mg daily [43] . Twenty-two of the 40 placebo arm patients entered this study; an initial 10 treated with low-dose bevacizumab alone and a subsequent 12 treated with low-dose bevacizumab plus thalidomide. There were no objective responses in either group and no significant difference in progression-free survival between the groups (2.4 months for bevacizumab alone versus 3.0 months for bevacizumab plus thalidomide; P = 0.63). Therapy in both arms was generally well tolerated with toxicity as expected for each agent. This trial failed to demonstrate additive or synergistic anti-tumor effects of these agents, but is noteworthy in the design that allowed relatively rapid evaluation of two agents in this setting.
Follow-up data has also been recently reported on patients in the original study [44] , providing insight into the feasibility of long-term dosing of bevacizumab in metastatic RCC. Four patients have been undergoing bevacizumab therapy without tumor progression for 3 to 5 years. Two patients completed a protocol-defined 2 years of therapy with tumor shrinkage, demonstrated tumor progression off therapy, and re-attained tumor regression with reinstitution of bevacizumab for an additional 3 to 3.5 years. Two additional patients achieved stable disease with bevacizumab dosing for 4+ years. Long-term toxicity has included primarily nephrotic range proteinuria with normal renal function in three of four patients.
Bevacizumab has been further investigated in combination with an anti-epidermal growth factor receptor (EGFR) strategy. TGF-a is HIF-regulated growth factor for RCC, with biologic effect through interaction with the EGFR [45] [46] [47] . Single agent studies, however, with agents directed against the EGFR receptor have demonstrated limited anti-tumor effect [48] . Nonetheless, preclinical investigation in human RCC xenograft models of bevacizumab and erlotinib, a small molecule EGFR inhibitor, have demonstrated potential benefit of combination therapy on tumor growth inhibition [49] , perhaps because EGFR resistance is mediated through VEGF [50] . A clinical trial in metastatic RCC with bevacizumab 10 mg/kg IV q 2 weeks in combination with erlotinib 150 mg PO QD reported a 25% partial response rate and a 66% stable disease rate [51 • ]. A recently completed randomized phase II trial of bevacizumab with or without erlotinib in untreated, metastatic RCC may provide further insight into potential additive synergistic clinical effect of this combination therapy.
Small molecule vascular endothelial growth factor receptor inhibitors
An alternative approach to VEGF inhibition involves small molecule tyrosine kinase inhibitors. These multi-targeted agents inhibit not only VEGFR, but also the PDGF receptor (PDGFR). received oral BAY 43-9006 400 mg BID, and patients with stable disease (defined as tumor burden within 25% of baseline by the sum of the bidimensional measurement of tumors) after 12 weeks of treatment were randomized to continue drug or receive placebo. Patients with $25% tumor shrinkage at 12 weeks continued open label BAY 43-9006. Of the 89 evaluable RCC patients who had reached the initial 12-week assessment, 13 patients (15%) achieved a partial response and 77% achieved stable disease per WHO criteria. A randomized, placebo-controlled phase III trial in cytokine-refractory RCC patients is ongoing and a similar trial in the adjuvant setting after nephrectomy is planned.
Conclusion
Clinical observers have long noted the variable natural history of renal cell carcinoma, from indolent stability to rapid growth and death from metastases. A growing understanding of the molecular biology has begun to further characterize this variable natural history. From the potential indolence of small renal masses to the rationally targeted therapeutic recently demonstrated to have a significant anti-tumor effect in RCC, it is clear that a more thorough understanding of the molecular basis of this cancer has led, and will continue to lead, to advances in clinical management.
